【Abstract】 Objective To study effect of levodopa combined with entacapone on serum interleukin (IL)1β and Cystatin(Cys)C in patients with Parkinson's disease.Methods 90 patients of parkinson's disease received therapy from June 2014 to June 2016 in our hospital were selected. According to random number table, those patients were divided into the observation group (n=45) and the control group (n=45). The control group was treated with levodopa, while the observation group was treated with entacapone. The IL-1β, Cys-C, UPSRS score, H-Y staging, quality of life(PDQ-39), clinical efficacy and adverse reaction were compared.Results After treatment, the levels of IL1βand CysC in the observation group were lower than that of the control group［（9.84±174）pg/ml vs（13.04±2.13）pg/ml，（1.05±0.21）mg/L vs（1.21±0.25）mg/L］（P＜0.05）. The UPSRS score, H-Y staging and quality of life PDQ39 score of observation group was lower than that of the control group［（8.14±1.73）score vs（11.79±1.84）score，（1.33±0.17）vs（1.64±0.24），（30.28±4.15）score vs（42.03±5.65）score］（P＜0.05）. The total effective rate of the observation group was higher than that of the control group［9556%（43/45）vs6667%（30/45）］（P＜0.05）. The incidence of adverse reactions in observation group was lower than that of the control group［17.78%（8/45）vs4000%（18/45）］（P＜0.05）.Conclusion Levodopa is effective for parkinson's disease, which can improve the motor function and quality of life, improve clinical efficacy. The mechanism may be related to the decrease of serum IL-1 and Cys-C,. The combined treatment can alleviate the adverse reaction of levodopa and get high safety.